Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06551116 · ClinicalTrials.gov registry record
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
A clinical trial of HER2-positive Metastatic Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 200
- Enrollment target
- 20
- Study locations
NCT06551116 is a study of HER2-positive Metastatic Breast Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 200 participants, above the 106-participant average among 11 other HER2-positive Metastatic Breast Cancer trials with a reported enrollment target (89% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06551116, a study of HER2-positive Metastatic Breast Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST CE-10-IVD
Study Locations (20)
Connecticut
- Smilow Cancer Hospital-Derby Care Center - Derby
- Smilow Cancer Hospital Care Center - Fairfield
- Smilow Cancer Hospital at Glastonbury - Glastonbury
- Smilow Cancer Hospital Care Center at Greenwich - Greenwich
- Smilow Cancer Hospital Care Center - Guilford
- Smilow Cancer Hospital at Saint Francis - Hartford
- Yale-New Haven Hospital North Haven Medical Center - New Haven
- Yale Cancer Center - New Haven
- Smilow Cancer Hospital Care Center at Long Ridge - Stamford
- Smilow Cancer Hospital-Torrington Care Center - Torrington
- Smilow Cancer Hospital Care Center - Trumbull
- Smilow Cancer Hospital-Waterbury Care Center - Waterbury
- Smilow Cancer Hospital Care Center - Waterford - Waterford
District of Columbia
- Georgetown University - Lombardi CCC - Washington D.C.
- MedStar Washington Hospital Center - Washington D.C.
- Sibley Memorial Hospital - Washington D.C.
Illinois
- University of Chicago Medical Center - Chicago
- University of Chicago Comprehensive Cancer Center at Silver Cross - New Lenox
- University of Chicago Medicine-Orland Park - Orland Park
California
- University of California San Francisco Medical Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2029-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06551116
The ClinicalTrials.gov registry entry for NCT06551116 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 106-participant average among 11 other HER2-positive Metastatic Breast Cancer trials with a reported enrollment target (89% higher). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2-positive Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CE-10-IVD is the first listed.
NCT06551116 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Connecticut, District of Columbia, Illinois.
Frequently Asked Questions
What is clinical trial NCT06551116 about?
NCT06551116 is a clinical study titled "QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer". This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
What is the current status of trial NCT06551116?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-10-10. Estimated completion is 2029-09-01.
What conditions does trial NCT06551116 study?
This clinical trial studies the following conditions: HER2-positive Metastatic Breast Cancer.
What interventions are being tested in trial NCT06551116?
The interventions under investigation include: CE-10-IVD (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06551116?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06551116 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
RECRUITING · NA
-
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
ACTIVE NOT RECRUITING
-
Testing a New Imaging Agent to Identify Cancer
ACTIVE NOT RECRUITING · Phase 1
-
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.